Financial Performance - iRhythm's revenue for Q3 2025 reached $192.9 million, a 30.7% increase compared to $147.5 million in Q3 2024[3, 5] - Gross profit for Q3 2025 was $137.1 million, up 35.1% from $101.5 million in Q3 2024, with a gross margin of 71.1%, a 230-basis point increase[6] - Net loss for Q3 2025 was $5.2 million, or a diluted loss of $0.16 per share, compared to a net loss of $46.2 million, or a diluted loss of $1.48 per share, in Q3 2024[8] - Adjusted EBITDA for Q3 2025 was $21.559 million, compared to $(19.886) million for Q3 2024[25] - Unrestricted cash, cash equivalents, and marketable securities totaled $565.2 million as of September 30, 2025[3, 9] Future Outlook - iRhythm projects full-year 2025 revenue between $735 million and $740 million[11] - The company anticipates an adjusted EBITDA margin for full-year 2025 ranging from approximately 8.25% to 8.75% of revenues[3, 11]

Core Insights - iRhythm Technologies reported a strong performance in Q3 2025, with revenue increasing by 30.7% year-over-year, reflecting the scalability of its platform and growing adoption of its technology across the healthcare ecosystem [3][4]. Financial Performance - Revenue for Q3 2025 was $192.9 million, up from $147.5 million in Q3 2024, driven by increased demand for Zio services [4]. - Gross profit for Q3 2025 was $137.1 million, a 35.1% increase from $101.5 million in Q3 2024, with a gross margin of 71.1%, improving by 230 basis points year-over-year [5]. - Operating expenses for Q3 2025 were $145.6 million, down from $151.8 million in Q3 2024, with adjusted operating expenses at $141.4 million compared to $143.8 million in the prior year [6]. - The net loss for Q3 2025 was $5.2 million, or a diluted loss of $0.16 per share, significantly improved from a net loss of $46.2 million, or a diluted loss of $1.48 per share, in Q3 2024 [7][8]. Cash Flow and Guidance - iRhythm achieved record free cash flow generation in Q3 2025 and anticipates being free cash flow positive for the entire year for the first time in its history [3]. - The company projects full-year 2025 revenue between $735 million to $740 million, with an expected adjusted EBITDA margin of approximately 8.25% to 8.75% [9]. Market Position and Innovations - The company continues to expand into primary care and population health programs, with progress in EHR integration and new clinical evidence supporting its leadership in proactive cardiac monitoring [3]. - iRhythm is advancing its innovation pipeline, including the submission of its next-generation Zio MCT solution to the FDA and early work in sleep diagnostics [3]. Research and Clinical Evidence - Recent publications, including the AVALON real-world evidence and AMALFI randomized clinical trial, reinforce the clinical value proposition of iRhythm's Zio long-term continuous monitoring service [7].